Trialmed Sp. z o.o.

Research site

Poland Solipska 27/ Lu 3, 02-482 Warsaw, Poland

5 trials recruiting
Graves' disease · Chronic spontaneous urticaria · Palmoplantar pustulosis
Adult patients

About Specializations

Trialmed Sp. z o.o. in Warsaw, Poland specialises in clinical trials of conditions such as Graves' disease, Chronic spontaneous urticaria, Palmoplantar pustulosis, Muscle hypertrophy, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Solipska 27/ Lu 302-482 WarsawPoland

Open in maps ↗

Recruiting now: 5 trials
Conditions studied: 9

More sites in Warsaw Poland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

11 clinical trials

Chronic spontaneous urticaria

Recruiting

A study to evaluate the effectiveness and safety of ritlecitinib tosilate and loratadine in adults with chronic spontaneous urticaria (hives)

Registered drug

A study to evaluate the effectiveness and safety of ritlecitinib tosilate and loratadine in adults with chronic spontaneous urticaria (hives)

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Loratadine
Sponsor:Pfizer Inc.

Contact Research Centre

Graves' disease

Recruiting

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Registered drug

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Efgartigimod Alfa
Sponsor:Argenx

Contact Research Centre

Graves' disease

Recruiting

Long-Term Study of Imeroprubart in Adults With Graves' Disease

InvestigationalNo placebo

Long-Term Study of Imeroprubart in Adults With Graves' Disease

InvestigationalNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Imeroprubart
Sponsor:Immunovant Sciences GmbH

Contact Research Centre

Graves' disease

Recruiting

Study of IMVT-1402 Treatment for Adults with Graves' Disease

Investigational

Study of IMVT-1402 Treatment for Adults with Graves' Disease

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Imeroprubart
Sponsor:Immunovant Sciences GmbH

Contact Research Centre

Palmoplantar pustulosis

Recruiting

Study of Delgocitinib Cream for Adults with Mild to Severe Palmoplantar Pustulosis: A 16-Week Treatment Trial

Investigational

Study of Delgocitinib Cream for Adults with Mild to Severe Palmoplantar Pustulosis: A 16-Week Treatment Trial

Investigational

Poland

Participants:18–64 years · 65+ years
Sponsor:Leo Pharma A/S

Contact Research Centre

Muscle hypertrophy

Not recruiting

Study of NT 201 compared to placebo in adults with moderate to severe platysma prominence

Investigational

Study of NT 201 compared to placebo in adults with moderate to severe platysma prominence

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
Sponsor:Merz Aesthetics GmbH

Contact Research Centre

Systemic lupus erythematosus

Not recruiting

Study of GLPG3667 for Adults with Active Systemic Lupus Erythematosus

Investigational

Study of GLPG3667 for Adults with Active Systemic Lupus Erythematosus

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:GLPG3667 fumarate
Sponsor:Galapagos

Contact Research Centre

Hidradenitis

Not recruiting

A Study to Evaluate the Safety and Effectiveness of Ritlecitinib Tosilate in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational

A Study to Evaluate the Safety and Effectiveness of Ritlecitinib Tosilate in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational

Poland

Participants:18–64 years · 65+ years
Sponsor:Pfizer Inc.

Contact Research Centre

Psoriasis

Not recruiting

Study on Adjustable Brodalumab Dosage for Patients with Moderate-to-Severe Plaque Psoriasis Weighing 120 kg or More

Registered drug

Study on Adjustable Brodalumab Dosage for Patients with Moderate-to-Severe Plaque Psoriasis Weighing 120 kg or More

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Brodalumab
Sponsor:Leo Pharma A/S

Contact Research Centre

Deafness neurosensory

Not recruiting

Study on the Effectiveness and Safety of AC102 Injection vs. Oral Prednisolone for Patients with Sudden Hearing Loss

Registered drug

Study on the Effectiveness and Safety of AC102 Injection vs. Oral Prednisolone for Patients with Sudden Hearing Loss

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Prednisolone
Sponsor:AudioCure Pharma GmbH

Contact Research Centre

Asthma

Not recruiting

Study on RPT193 for Adults with Moderate-to-Severe Asthma Partially Controlled by Inhaled Corticosteroids and Long-Acting Beta 2 Agonists

Registered drug

Study on RPT193 for Adults with Moderate-to-Severe Asthma Partially Controlled by Inhaled Corticosteroids and Long-Acting Beta 2 Agonists

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Salbutamol Sulfate
Sponsor:Rapt Therapeutics Inc.

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites